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Abstract—There is much current debate surrounding the use of non-human primates (NHPs) in
medical research and drug development. This review, stimulated by calls for evidence from UK-based
inquiries into NHP research, takes a critical view in order to provide some important balance against
papers supporting NHP research and calling for it to be expanded. We show that there is a paucity of
evidence to demonstrate the positive contribution or successful translation of NHP research to human
medicine, that there is a great deal of often overlooked data showing NHP research to be irrelevant,
unnecessary, even hazardous to human health and to have little or no predictive value or application
to human medicine. We briefly discuss the reasons why this may be so, reflect upon the consequences
for future medical progress and, on the basis of our findings, suggest a more scientifically robust and
promising way forward.
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INTRODUCTION
Such is the current level of controversy surrounding the issue of NHP exper-
imentation, that in recent years a number of inquiries have taken place into
the practice. For example, in December 2002 the Animal Procedures Com-
mittee (APC) in the UK published a report containing recommendations for its
future (Animal Procedures Committee, 2002); earlier this year the committee
held and published the proceedings of a subsequent stakeholders’ forum, for
which it has invited comments (Home Office Primates Stakeholder Forum, 2004).
Also, in March 2005 a new committee was set up to examine the scientific ba-
sis of NHP experimentation, for which submissions of evidence were invited
(http://www.nhpstudy.com/call_for_evidence.pdf). This is to be warmly encour-
aged; only by objectively questioning and evaluating scientific methodologies with-
out bias can we hope to ensure that it is of optimal efficacy and likely to achieve
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its long-term goals. At the same time, we must be conscious of who commissions,
oversees and publishes such reports: objectivity is often compromised by vested
interests. Nevertheless, such inquiries at least provide an opportunity for the airing
of views across the whole spectrum, and some assessment is better than none at all.
It is fair to say that, were it not for these inquiries, it would be left to NHP research
reports in the scientific literature to shape scientists’ views. Arguably, this area of
endeavour suffers more than most from the ‘positive bias’ that affects the publica-
tion policies of many journals, perhaps due to the attention that is focussed on it. In
taking a critical, yet still balanced and comprehensive stance in this review, which is
drawn from submissions of evidence to the above two inquiries, we hope to redress
this balance to some degree while at all times maintaining a scientific and factual
attitude to stimulate debate on the matter.
Many papers reveal findings that, while constituting interesting contributions to
the scientific knowledge-base, are not relevant or applicable to human medicine. To
be of use and scientifically justifiable they must be predictive of the human situation,
providing information that is capable of translation to the clinic. Many studies
provide only fortuitous ‘experimental confirmation’ of previously known human
clinical data, or are championed when they correlate retrospectively with human
studies. In both of these cases, or when the reported studies have demonstrated
fundamental inter-species differences, the authors’ conclusions tend towards crucial
‘further work’ based, naturally, on more experiments involving NHPs. We suggest
that a more critical approach would be more beneficial to medicine, and we provide
a brief outline of such an approach here.
USE OF NON-HUMAN PRIMATES IN DRUG DEVELOPMENT/TOXICOLOGY
The major use of NHPs remains as the ‘second species’ of animal in pre-clinical
safety assessment of new drugs. In spite of such testing, the attrition rate of drugs
entering human clinical trials is 92% (Harding, 2004). Many drugs that do pass the
clinical trial phase to reach the market place have a questionable safety profile:
adverse drug reactions (ADRs) remain the fourth biggest killer in the western
world, despite apparent safety in animal (often NHP) models (Lazaru et al., 1998).
Important examples include:
• Hormone Replacement Therapy — prescribed to millions of women, and thought
to protect against heart disease and stroke on the basis of NHP experiments, HRT
is now known to increase the risk of these diseases, as well as breast cancer in
humans. The Chairman of the German Commission on the Safety of Medicines
described HRT as ‘the new Thalidomide’. It has caused up to 20 000 cases of
breast cancer over the past decade in Britain alone (Gray, 2003).
• AIDSVAX — after successful results of this HIV vaccine in chimpanzees, it
failed to protect any of the 8000 human volunteers in clinical trials.
• Teratology (risk of birth defects) — in the wake of Thalidomide, animals, often
NHPs, have been used to assess the risk of foetal damage during pregnancy as
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a result of exposure to drugs and other chemicals. Results from NHPs correlate
with known human teratogens only 50% of the time, less even than results from
more evolutionarily distant species such as rats, hamsters and ferrets (Schardein,
1993; Bailey et al., 2005). Aspirin, for example, is teratogenic in monkeys though
not in humans.
• Asthma — Isoprenaline doses, derived from animal data, were too high for
humans and killed thousands of people; mainly children. An attempt to replicate
this in NHPs was completely unsuccessful (Carson et al., 1971).
• Opren (for arthritis) killed 61 people and harmed over 3500, despite showing no
problems in NHPs (Eason et al., 1990).
• Flosint (another arthritis drug) caused hundreds of severe ADRs and several
deaths, despite being well tolerated in NHPs (Mann, 1984).
• Carbenoxalone (for gastric ulcers) caused heart failure, which could not be
replicated in NHPs (Eason et al., 1990).
• Amrinone (for heart failure) caused severe haemorrhaging in 20% of long-term
patients, despite showing no warning signs in NHPs (Eason et al., 1987).
These statistics and examples are of no surprise when one considers comprehen-
sive studies of comparative drug toxicology, which have revealed levels of discor-
dance between results from animals and humans of between 67 and 96% (Lumley
and Walker, 1990; Spriet-Pourra and Auriche, 1994). These studies show that an-
imal (or NHP) based toxicology is not predictive of human response; providing
correct predictions less often than a coin toss.
Among scientists in academia and in the pharmaceutical industry itself, the inabil-
ity of animal-based pre-clinical models (including NHPs) to assess human ADMET
properties (how a drug is Absorbed, Distributed, Metabolised and Eliminated, and
its Toxicological properties) has been acknowledged for decades:
• Dr. Brimblecombe of Smith Kline and French commented in 1981, ‘. . . the
present tests are well known to us but that does not make them good. There may
be better tests around, but we have no incentive whatsoever to look for them at the
moment. In fact, quite the reverse [because of the fear that regulatory agencies
will require the new tests in addition to the current ones] (Brimblecombe, 1981)’.
• Professor Caldwell of St. Mary’s Hospital Medical School, London observed,
‘It has been obvious for some time that there is generally no evolutionary basis
behind the particular-metabolizing ability of a particular species. Indeed, among
rodents and primates, zoologically closely related species exhibit markedly
different patterns of metabolism (Caldwell, 1992)’.
• William Bains, chief scientific officer of Amedis Pharmaceuticals (Cambridge,
UK) estimates that 50% of all drugs in development fail to progress to the market
because of problems associated with ADMET and 50% of all drugs that do make
it to market have problems associated with ADMET (Hodgson, 2001).
• Drs Palfreyman, Charles and Blander in ‘Drug Discovery World’ observed
that ‘One of the major challenges facing the drug discovery community is the
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limitation and poor predictability of animal-based strategies . . . many drugs have
failed in later stages of development because the animal data were poor predictors
of efficacy in the human subject . . . . One of the overriding interests of the
pharmaceutical and biotechnologies industry is to create alternative development
strategies that are less reliant on poor animal predictor models of human
disease . . .’ (Palfreyman et al., 2002).
Marmosets are often the ‘second species’ of choice — not due to any outstanding
scientific properties or especially predictive qualities but because they are small,
cheap and relatively easy to house and breed (Smith et al., 2001). In fact, the validity
of NHP use in this way has been questioned recently in several quarters:
• The Toxicology Working Group of the House of Lords Select Committee on
Animals in Scientific Procedures stated ‘the formulaic use of two species in safety
testing is not a scientifically justifiable practice, but rather an acknowledgement
of the problem of species differences in extrapolating the results of animal tests
to predict effects in humans’, and ‘the reliability and relevance of all existing
animal tests should be reviewed as a matter of urgency’ (House of Lords Select
Committee on Animals in Scientific Procedures, 2002).
• The Boyd Group concluded that ‘any use of NHPs in research and testing
requires very strong justification’ and recommended that the APC ‘examine
retrospectively any application or licence to use non-human primates, with a view
to informing future ethical judgements’ (Boyd Group papers, 2002).
• The Nuffield Council on Bioethics concluded that ‘there is a need for continuing
review of the scientific case for using animals in research and testing. It
is axiomatic that any such use should be accompanied by active and critical
reflection on the validity and relevance of the models and research studies’
(Nuffield Council on Bioethics, 2005).
In addition, the Animal Procedures Committee produced a series of wide-ranging
recommendations and associated observations following their aforementioned in-
quiry (Animal Procedures Committee, 2002). Many of these are briefly summarised
below, along with some relevant thoughts and criticisms:
• “The development and implementation of non-animal alternatives to replace
the use of non-human primates must be accepted within industry and the
international regulatory arena as a high priority goal”.
The committee are to be applauded for this recommendation, and also their
insistence that industry ‘can do better’, that non-animal alternatives might constitute
‘better science’ and their conclusion that there are major advantages to be gained
from the replacement of NHPs.
However, they also concluded that there are ‘no quick wins in sight’, suggesting
a concentration of scientific effort in the near future on reduction and refinement in
preference to replacement, and that gains in the former ‘2 Rs’ are more likely in
the short term than gains in the latter. These ‘gains’ might be true if the focus is
restricted to animal numbers and/or suffering, but any gain with regard to human
Non-human primates in medical research and drug development: a critical review 239
health is questionable at best. If we acknowledge that ‘better science’ is a tangible
advantage of the acceptance, development and implementation of non-animal
alternatives, then it is surely counter-productive to divert attention and resources
away from replacement in favour of reduction and refinement. There is substantial
and increasing evidence that animal models are not scientifically justifiable, and
therefore their refinement and reduction is highly unlikely to translate to any benefit
for human medicine.
In the opinion of a growing number of scientists, replacement is the only valid way
forward and a multitude of technologies has already been developed to facilitate
this. When used together, these are clearly more predictive of the human situation
than the animal (and often NHP) models that are current standard practice. For
example, recent advances with microarray technology allied to computer learning
methods have shown huge promise in toxicity testing. One group developing this is
SimuGen (Cambridge, UK), who have stated a view shared by many, “The proof is
overwhelming that it will work . . . the long term plan is to replace animal testing
. . . the technology is already there, but drugs regulators are very strict as to what is
appropriate and safe.”
• “We believe it is essential to instigate a detailed examination of regulatory
policies on species selection in toxicity testing . . .”
An examination of this type, in conjunction with full disclosure of the policies of
regulatory authorities, would be of real scientific value. It has been argued long and
hard by thousands of concerned scientific and medical professionals that it is not
scientifically possible to reliably extrapolate findings from one species to another.
This conviction was echoed by the Toxicology Working Group of the House of
Lords select committee on Animals in Scientific Procedures (House of Lords
Select Committee on Animals in Scientific Procedures, 2002), whose comments are
detailed above, as are observations along similar lines from the Nuffield Council on
Bioethics (Nuffield Council on Bioethics, 2005).
• “The forum understood that the thinking behind this APC recommendation
was that pharmaceutical companies often used primates for reasons other than
scientific necessity”.
The evidence for this view is that the scientific necessity of NHP use has never
been demonstrated by those that advocate it. In fact, in addition to myriad
examples illustrating the folly of NHP use, there is anecdotal evidence to embarrass
those advocates. For example, Dr. Robert Ruffalo, President of R&D at Wyeth,
cited at an international conference in March 2005 an example involving the
pneumococcal vaccine Prevnar. Successfully used in over 30 million American
children since the year 2000, the human epidemiological data were of no interest
to Japanese regulatory authorities, who required new NHP data instead. Indeed,
the fact that human trials often take place concurrently with or even prior to animal
toxicology is evidence that animal tests are performed for regulatory, rather than
scientific, reasons. Further evidence is provided by the Association of the British
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Pharmaceutical Industry in a paper entitled ‘The selection of marmoset monkeys in
pharmaceutical toxicology’ (Smith et al., 2001) which documents considerations of
cost, practicality and convenience as reasons for their use.
• “There may be a transient, but significant, increase in animal numbers whilst
information to inform discussion of suitability was gathered on the basis of
comparative studies”.
After decades of animal-based toxicology, there is more than enough data with
which to perform comparative studies, such as those mentioned above (Lumley
and Walker, 1990; Spriet-Pourra and Auriche, 1994). Last year a review of the
evidence that animals are reliable predictors of toxic effects in humans found the
evidence to be ‘fragmentary’, pointing to ‘significant over- and under-prediction of
adverse effects from animal studies that varies with the particular organ or system’.
Furthermore, it showed the false positive rate to be astonishingly high: even in
NHPs it exceeded the success rate in two-thirds of the forms of toxicity studied
(Greaves, 2004).
• “The Home Office should insist that a full range of in vitro toxicokinetic/meta-
bolism screening be done before . . . the selection of a second (non-rodent) species
for drug safety evaluation”.
The committee’s decision that a full range of in vitro ADMET (how a drug is Ab-
sorbed, Distributed, Metabolised and Eliminated, and its Toxicological properties)
studies be made obligatory during the course of drug development is laudable. How-
ever, there is a strong argument that the range, diversity, relevance and performance
of batteries of powerful in vitro, in silico, human ex vivo, microdosing and other
studies negate any data that can be provided from animal models; it follows that
using data that is directly relevant to humans as the basis for the choice of a poorly
predictive animal model is of questionable scientific merit. Scientific justification
for the use of a particular animal species against human-specific methods, rather
than simply against another animal species, would be far more apposite. Scien-
tists in academia and in the pharmaceutical industry itself have acknowledged for
decades the inability of animal-based pre-clinical models (including NHPs) to as-
sess human ADMET properties, as discussed above.
• “It was recognized and acknowledged that tremendous progress has been made
in identifying and progressing appropriate preliminary studies and that industry
deserves credit”.
Credit must be given to those who have conceived and developed many of the
studies and tests that provide more pertinent and reliable data to aid in the
prediction of human drug response. In this way, drugs are being and have
been developed precluding any reliance on animal pre-clinical data, at least until
regulatory guidelines demand it: examples include anti-HIV protease-inhibitor and
nucleoside-analogue drugs (DeVita et al., 1992; Mitsuya et al., 1985; Seelmeier
et al., 1988; Soudeyns et al., 1991; Roberts et al., 1990; Vacca et al., 1994),
some of which are known to have ADMET properties that vary wildly between
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animal species and that can be particularly dissimilar in NHPs (Chiba et al.,
2000); Novartis’ leukaemia drug Glivec that was designed and developed in vitro
(Druker and Lydon, 2000; Druker et al., 1996; Geissler et al., 1992; Lydon
et al., 1990), and several drugs in the development pipeline from the company
Pharmagene, one of which, for cystic fibrosis (PGN0052) is in late-phase clinical
trials (http://www.pharmagene.com/).
• “The availability of animal tissue for comparative in vitro studies should be
improved and we urge the pharmaceutical industry, the Home Office and ERPs
to promote in-house tissue sharing and further promote tissue banks”.
The committee’s encouragement of the use of human tissues, which are read-
ily available through numerous channels such as the UK Human Tissue Bank
(http://www.ukhtb.org), members of the British Association for Tissue Banking
(http://www.batb.org.uk/), and various commercial suppliers, will have a far more
significant positive scientific impact.
• “The use of highly sensitive analytical methods to provide human pharmacoki-
netic data should be further developed and the resources provided to move tech-
nologies from the research phase to the stage where they can be routinely used.
Early ultra-low dose studies in human volunteers should be encouraged”.
There can be no argument with this recommendation; even the Food and Drug
Administration (FDA) has accepted that ‘the tools of the last century are being
used to develop the drugs of the 21st (http://www.fda.gov/oc/initiatives/criticalpath/
whitepaper.html).
Concerns were raised, however, about limitations of these techniques; about
increased animal use in later stages of development if more drugs pass the screening
process; about the expense, infancy and limited availability of microdosing; and
about predictability and human safety, and these issues must be addressed.
All scientific techniques used in drug development have limitations; the critical
question to ask is which combination of them provide the most relevant, predictive
and reliable data with which to proceed to clinical trials. Currently the drug
development process is heavily animal-based, relying on methods that correlate
poorly with the human response, which is largely responsible for the fact that over
90% of drug candidates fail during human clinical trials. As discussed earlier, a
comprehensive battery of human-specific tests presents us with the shortest ‘leap of
faith’ possible when proceeding to the clinical phase of development. To continue
using animal (often NHP) models that have never been validated and with all their
limitations, while insisting upon extreme validation criteria for alternative methods
is unscientific.
One of the objections of the APC forum, that more animals would be used in
pre-clinical development if prior human-based screening and discovery methods
were adopted, is not a valid reason to resist them even if this were true. More
pertinent human-based screening and discovery methods would help to deliver the
‘fail early, fail cheap’ holy grail of the pharmaceutical industry, leading to the
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progression of fewer compounds, but better compounds, to clinical trials where the
real expense lies. If drug companies extended this human-centric approach to the
development phase, as they could and should, they may well find such compounds
have a lower chance of adding to the adverse drug reaction (ADR) statistics that are
now responsible for harming and killing a number of people beaten only by cancer,
heart disease and stroke. With regard to the ‘predictability’ and ‘human safety’
concerns of the forum, moving away from animal-based methods is surely critical
to address these.
Events have shown the forum’s concerns about microdosing to be unfounded.
Even if expense were a genuine issue, it ought to be a pharmaceutical company’s
foremost concern that any drug they develop is launched with the best human
efficacy and safety data available. It is perhaps timely here to reiterate the burden of
expense in the pharmaceutical industry; R&D costs are typically one-quarter of the
advertising and marketing budget, and only 15% of this is for pre-clinical studies.
So if expense is not a real issue, is the relative infancy of the technique itself?
Notably, microdosing was recently rigorously tested with five drugs known for
their difficult pharmacokinetic properties, in a trial designed for the technique to
be unlikely to succeed. This ‘CREAM’ (Consortium for Resourcing and Evaluating
AMS Microdosing) trial was pronounced a real success (http://www.xceleron.co.uk/
metadot/index.pl?id=2224&isa=Newsitem&op=show), and the technique has also
been given a seal of approval by the FDA (April 2005) and the European Agency
for the Evaluation of Medicinal Products (EMEA, January 2003).
• “The use of primates in the safety assessment of pharmaceuticals can clearly
only be justified under current UK legislation if the data obtained are both
valid (relevant for humans) and necessary in order for a safety assessment to be
made. Validity and necessity should be continuously monitored by retrospective
comparison of test data with clinical experience, and the need for studies
specifically on primates should be critically assessed before tests are carried
out”.
Validity and relevance for humans are surely pre-requisites for any techniques used
in the safety assessment of drugs. It is incredible, therefore, that so little analysis of
these aspects has been carried out for what is an intrinsic part of drug development.
Earlier in this document were summarised some of the studies done to date. In
addition, the Olson study cited by the APC (Olson et al., 2000) found that if a
side effect occurred in humans, there was an animal that it also occurred in about
70% of the time. Of course in retrospect it is simple to find an animal from all
available species used in toxicology that replicates the human condition. Prediction,
knowing in advance which species will be suggestive of the human condition
is another matter, and this is where the animal model fails. The Greaves study
(Greaves et al., 2004) cited earlier revealed an alarmingly high false positive rate.
It also does not stand up to statistical scrutiny: much of the evidence supporting the
predictive nature of animal toxicity was derived from an earlier study (Schein et al.,
1970) with incorrectly calculated false positive and false negative rates (Personal
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communication from professional statistician). Correctly manipulated statistics
actually demonstrate that dogs and monkeys, even when the results are taken in
tandem, are no more predictive of human toxicity than a coin toss; they give no
weight of evidence to prior odds that a particular compound is toxic to humans, and
they actually show that toxicity results for animals (including NHPs) and humans
are independent of one another.
It is therefore already abundantly clear, despite the relative paucity of studies that
have examined the plethora of toxicological data available, that animal studies in
pre-clinical drug development are neither valid for nor relevant to humans. Often,
data from NHPs, our closest genetic relatives, correlates with human data less than
that from other more distant species. Even Ralph Heywood, former director of
Huntingdon Research Centre, stated ‘the best guess for the correlation of adverse
reactions in man and animal toxicity data is somewhere between 5 and 25%’.
• “The predictive value of data from primate studies should be investigated by
comparing the results of pre-clinical and clinical studies on drugs that have
progressed to clinical use”.
“Such a comparison could provide an indicator of study validity with respect to
materials that subsequently make it into humans”.
This information would be essential in helping to determine the true predictive
value of NHPs as a pre-clinical model, but would of course only provide limited
information: many ‘False Positive’ compounds would be missed because they did
not progress to clinical trials. This endeavour, however, would serve to confirm
beyond doubt whether the use of NHPs (and indeed other animals) in pre-clinical
toxicology is a scientifically justifiable undertaking. More evidence of this type
would hasten the move towards the most effective drug development methodologies,
translating to safer and more effective drugs for society.
The concerns of certain members of the forum in this instance were insubstantial:
• “Simply acquiring the data would not provide sufficient information to critically
appraise decisions on whether or not to use primates”.
Acquiring these data is essential, and is better than doing nothing at all to
scientifically appraise primate use. Put simply, NHP data is either predictive (as
it should be) or not. If this data shows a lack of correlation, then the data is not
predictive, and NHP use is not justifiable.
• “An informed choice of second species would have been made before the data
was generated, and it would be difficult to determine what the findings might
have been if another species had been used”.
This is a salient point in the scientific argument against the use of NHPs and animals
in general; one cannot determine what the findings might have been for another
species because it is impossible to extrapolate such data between them; this includes
humans.
• “As clinical studies are not designed to produce or evaluate toxic effects in
humans, correlation of findings related to toxicity would not be expected”.
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This is an extraordinary claim: clinical studies may not be designed to produce toxic
effects, but one of their accepted and important roles is most certainly to evaluate
those that do occur. Many ADRs are detected during clinical trials, and these can be
retrospectively compared with those arising in pre-clinical NHP models: correlation
is then possible.
If, as claimed above, clinical trials are not designed to evaluate toxic effects then
it must be assumed that this is one of the roles of pre-clinical animal models. Once
again, the lack of predictivity of animal toxicology, the numbers of reported deaths
in clinical trials despite extensive animal data (Marshall, 2000), and the increasing
rates of morbidity and mortality from ADRs must be considered.
• “As the findings in the second species can prevent materials reaching clinical
trials, and prior to this many compounds will already have been screened out
based on other species’ toxicity/ in-vitro/in-silico, such a study would also not be
informative about the decisions not to proceed to humans taken on the basis of
the findings in the second species”.
Findings in the first species do not always signal the end of the drug assessment
process, and so important comparative information between animal species could
be gathered. This information could further be used to assess the correlation and
predictive nature of the animal models with regard to humans, for example when
compounds proceed to clinical trial despite some adverse findings in the animal
models, or in cases where compounds ‘pass’ the animal-based tests but fail in
clinical trials.
• “The design and sequence of pre-clinical safety studies needs to be reviewed. We
ask the Home Office to consider whether measures need to be taken to prevent
overlap of rodent and non-rodent studies, actively discouraging any simultaneous
testing in rodents and primates in order to shorten the time course of drug
development”.
A review of the practices involved in pre-clinical studies is long overdue, and
absolutely essential in light of the current level and rate of growth of ADRs.
However, the focus should not be on a simple alteration of a protocol that tacitly
accepts the worth of animal (including NHP) models: the increasing amount of
negative evidence with regard to the scientific validity of these, coupled with
technological advances that have presented many better alternatives, surely demand
that nothing short of a complete overhaul will suffice.
• “However, tests on rodent species can fail to identify toxic effects (which will
more accurately predict the effect on man) found in primates”.
Tests on rodent species cannot predict toxic effects found in NHPs; they can fail to
correlate with them, and often do. It follows that there is also a poor correlation
between rodents and humans, and of course between NHPs and humans. Such
poor correlation is found between all species, and even between different strains of
the same species, and is responsible for the complete lack of predictivity between
species. Statistics do not support the statement made above by the forum that toxic
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effects found in NHPs more accurately predict the effect on man; therefore, the
earlier statements above concerning a complete overhaul of pre-clinical studies, the
support for this from the House of Lords Select Committee on Animals in Scientific
Procedures (2002) and the Nuffield Council on Bioethics (2005), and other statistics
and quotations above that constitute much of the evidence base for this, take on more
importance.
• “Species selection is important for both ethical and scientific reasons; and it must
be made on a sound scientific basis”.
“Since pharmaceuticals are being developed for use in the human, the most
appropriate species will be the one that most closely resembles the human”.
“. . . the Primates sub-committee considers for the reasons set out in chapter 3
of the report that the choice is currently insufficiently justified. We consider that
this problem is significant . . .”.
Taking into account the arguments detailed above, the only species that is scientifi-
cally justifiable for selection is Homo sapiens. The argument for animal-based pre-
clinical testing has always been the necessity of testing in a ‘whole system’. When
the available whole systems are quite clearly, in every respect, the ‘wrong systems’,
this argument fails to hold. This can be illustrated by a revision of the small number
of examples listed earlier, of how species differences between humans and NHPs
have resulted in human harm.
NON-HUMAN PRIMATES IN HUMAN DISEASE RESEARCH
NHP research on the three leading killers; heart disease, cancer and stroke, has
failed to yield significant insights about the diseases in humans, or to produce
drugs to treat them. The scientific literature is replete with examples of NHP data
confounding human disease research by conflicting with known human data or by
leading research up ‘blind alleys’, or even by causing human harm when translated
to the clinic. Looking briefly at some of the major areas of NHP use:
• Stroke occurs as a result of atherosclerosis, but atherosclerotic plaques do not
form in NHPs. Artificial induction of stroke-like situations in NHPs have
served as a model of stroke research for decades, despite critical physiological
differences such as collateral blood flow. Significant species-specific and even
strain-specific differences in response to ischaemic injury exist (Huang et al.,
2000), and despite dozens of candidates, not a single effective therapy has been
successful in humans, despite efficacy in NHPs (Neff, 1989; Wiebers et al.,
1990a, b).
• Parkinson’s Disease (PD) has been studied using neurotoxic chemicals to induce
superficial PD-like symptoms, predominantly in marmosets and macaques. Fun-
damental differences in the onset, type, and persistence of symptoms exist in all
models, in addition to physiological differences such as the absence in NHPs of
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Lewy Bodies. Species differences are known to play a role in the clinical ex-
pression as well as in the cellular specificity of the lesions; for example, striatal
degeneration in humans is frequently associated with dyskinesia, whereas stri-
atal excitotoxic lesions alone are not sufficient to induce dyskinesia or chorea in
NHPs. Also, the time course of nerve cell degeneration, which normally evolves
over several years in neurodegenerative diseases in humans, is for practical rea-
sons replaced by a much shorter period of time in NHP models (Hantraye, 1998).
The major breakthroughs for PD have been via epidemiology, clinical studies, ge-
netic research, human tissue studies and autopsies. Space precludes detail here,
but these have resulted in the discovery that levodopa crosses the blood-brain
barrier then converts into dopamine, that its efficacy in treatment of PD patients
diminishes due to progressive degeneration of the D3 dopamine receptor, and that
there seem to be a number of genetic and environmental predispositions/causes.
Additionally, deep-brain stimulation (DBS), often claimed to have been devel-
oped through critical NHP experiments, was actually discovered serendipitously
in a human patient and owes nothing to NHPs for its advancement (Benabid et al.,
1987, 1989).
• Alzheimer’s disease (AD) is another human ailment for which progress has
been confounded and hampered by animal (including NHP) research. Many
scientists have spent years trying to create a ‘good’ AD animal model; not
only has this been a failure (Conner and Tuszynski, 2000; Lindholm, 1997;
Snowdon et al., 1997), but very little progress has been made in understanding
the various pathologies associated with the disease. For example, mouse
experiments suggested that tau protein was unlikely to be of any importance,
though this is now known to be highly species-specific (Guela et al., 1998),
and plaques and tangles in the brain are the hallmark of Alzheimer’s disease in
humans but not in monkeys (St. George-Hyslop and Westaway, 1999). Human
clinical research, epidemiological studies and in vitro techniques gave rise to the
cholinergic hypothesis for AD, and revealed AD-associated decrease in choline
acetyltransferase (ChAT) activity, and links with the presenilin 1, presenilin 2 and
APOE-e4 genes, and vitamin B12/folate deficiency and high fat/high cholesterol
diets. None relied on the use of NHPs or other animals.
NHP use can also cause direct human harm, in addition to delaying progress and
diverting research funds from more relevant methods. The once much-vaunted AD
‘vaccine’ AN-1792 (AIP-001) dramatically slowed brain damage in an AD mouse
model, and ’was well tolerated when tested in several animal species, including
monkeys’ in experiments prior to clinical trials (Sibal and Samson, 2001; Young,
2002). Despite the encouraging NHP data, clinical trials were suspended following
CNS-inflammation and ischaemic strokes in 15 participants (Steinberg, 2002).
These situations have arisen because, quite simply but crucially, genes in the
brains of humans and non-human primates, including chimpanzees and rhesus mon-
keys, differ in their levels of activity. These differences in brain activity between
humans and monkeys can be traced right down to the molecular level, supporting
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the thesis that all animal species exhibit unique biological activities arising from
their particular genetic make-up; and the smallest genetic difference or peculiar-
ity can manifest as profound species differences. Interestingly, human genes ex-
hibit greater protection against activity-related damage compared to monkey brains.
This could help to explain why humans live longer than non-human primates and
also why humans are more susceptible to age-related neurodegenerative diseases,
such as Alzheimer’s and Parkinson’s (Emory University Health Sciences Center
press release, 2003). Other major differences between humans and NHPs, partic-
ularly neurological differences, are now being elucidated that explain definitively
why the latter can not serve as disease models for human beings. With regard to
AD, humans and great apes for example possess a particular type of projection neu-
ron in the anterior cingulate cortex, which is known to be severely affected in the
degenerative process of Alzheimer’s disease (Nimchinsky et al., 1999). Also, the
neuropeptide galanin that regulates cholinergic basal forebrain (CBF) function dif-
fers in its chemoanatomic organisation across species: in monkeys, all CBF neurons
coexpress galanin, whereas in apes and humans galanin is found within a separate
population of interneurons that are in close apposition to the CBF perikarya (Muf-
son et al., 1998). Because galaninergic fibres hyperinnervate CBF neurons in AD
inhibiting acetylcholine release in the hippocampus, it may exacerbate cholinergic
cellular dysfunction in AD. This difference could be critical when attempting to
create an NHP AD model.
It is perhaps because of such evidence that many experts are now concluding that,
in the words of Dr. John Xuereb, director of the Cambridge Brain Bank Laboratory,
‘Alzheimer’s, Parkinson’s and other neurodegenerative diseases occur in humans
and it is in human tissue that we will find the answers to these diseases’ (BBC
Radio Cambridge, UK, 2002).
• AIDS — NHPs do not develop AIDS when infected with HIV. Despite this fact,
NHPs continue to be used in HIV/AIDS research, often with the ‘related’ simian
immunodeficiency virus (SIV), or an artificial hybrid of the two (SHIV). As with
so many artificially-induced animal models of human diseases, the differences are
too profound to allow any resulting data from them to be extrapolated to humans
(Kaufman et al., 1996). For example:
– Infection progresses at a different rate in SIV/SHIV infected monkeys com-
pared to HIV-infected humans.
– Some proteins from the coat of the virus have vaccine-like effects in monkeys,
but not in people.
– Chimpanzees have an alteration in their DNA that makes their immune systems
detect and respond to HIV and SIV viruses differently (Anzai et al., 2003).
– The lymph nodes of HIV-infected people undergo structural changes and
contain deposits of the virus; neither occurs in chimpanzees (Koopman et al.,
1999).
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– Humans and chimpanzees have different ratios of crucial blood cells called
T-lymphocytes.
– There are important differences in the cellular receptors involved in the
infection process (Nath et al., 2000).
Because of these and many other differences, none of 30-plus vaccines (mostly
tested in NHPs) has proved safe and effective in over 70 clinical trials. Recently,
the ‘Aidsvax’HIV vaccine failed to protect 8000 high-risk human volunteers despite
proving efficacious in chimpanzees’ (Wilson, 2003). In fact, some candidate anti-
virals screened using in vitro methods have gone directly into humans with little
supportive in vivo data from prior animal experiments. One of the reasons is that
there is no predictive animal model for HIV infection in humans (Wyand, 1992).
Some scientists have acknowledged that even chimpanzees are unlikely to prove
useful as animal models for understanding the mechanism of infection or means of
treatment (Stott and Almond, 1995). Dr. Thomas Insel, as director of the Yerkes
Primate Centre, admitted that 15 years of work in chimps has produced little data
relevant to humans (Smaglik, 1999). The US Government, following a 10-year
expert review, concluded that chimpanzees are a deficient model and redirected $10
million of funding. Dr. Bolognesi of Duke University, USA, stated ‘No animal
models faithfully reproduce . . . HIV infection and disease in humans, and the
studies of experimental vaccines in animal models . . . have yielded disparate results’
(Bolognesi, 1994). In the opinion of a US-based group of researchers, ‘the testing
of vaccines and drugs in more animals will not be helpful if in the end these animals
do not closely resemble humans. Even a vaccine that has 100% efficacy in [NHPs]
. . . might still be ineffective in humans. Conversely, a proficient vaccine developed
in humans might never show benefit in the animal models’ (Nath et al., 2000).
Dr. Mark Feinberg, a leading AIDS researcher, summed it up thus: ‘What good
does it do you to test something [a vaccine] in a monkey? You find five or six years
from now that it works in the monkey, and then you test it in humans and you realise
that humans behave totally differently from monkeys, so you’ve wasted five years’.
In common with many other human diseases, everything we know about HIV
and AIDS has been discovered without relying on animal models. Effective HIV
protease-inhibitor and nucleoside-analogue drugs were conceived and developed
using in vitro and in silico methods (DeVita et al., 1992; Mitsuya et al., 1985;
Seelmeier et al., 1988; Soudeyns et al., 1991; Roberts et al., 1991; Vacca et al.,
1994).
• Hepatitis — Hepatitis C virus (HCV) has infected hundreds of millions of people
worldwide, and is a major cause of chronic liver disease. Chimpanzees have his-
torically borne the brunt of HCV research, even though they respond to the virus
very differently to humans. For example, significant and confounding differences
have been reported in mother-infant transmission between humans and chim-
panzees (Zanetti et al., 1995); chronic infection occurs much more frequently
in humans (Major and Feinstone, 2000) humans progress to liver fibrosis and
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cirrhosis while chimpanzees do not, and humans suffer from hepatocellular car-
cinoma as a result of HCV though it is very rare in chimpanzees (Lanford et al.,
2001). Naturally there are some similarities (in terms of liver response, for ex-
ample), though the question must be asked (as with all animal models) if these
similarities are sufficient to pursue relevant research that will lead to successful
treatments.
In common with NHP models of many other human infectious diseases, the
contribution of NHP experiments to treatment of HCV infection, especially
with regard to vaccine development and understanding the mechanisms of
hepatocellular damage, has been a failure (Rosen and Martin, 2000) with most
of the progress made relying on in vitro and clinical studies. It must be
stressed again that retrospective correlations between human-based knowledge
and animal models are of no value. Now, with the recent breakthrough in the
development of a successful in vitro culture system for the virus (Sun et al., 2004;
Zhong et al., 2005), vaccine development is likely to accelerate as it did for other
viruses such as polio and measles (Gallo, 1991).
Infectious disease research in NHPs or indeed, in any animals other than humans is
almost guaranteed to fail because infectious agents are highly species specific. For
instance, chimpanzees are essentially immune to the human AIDS and Hepatitis B
and C viruses as detailed above, plus the malaria parasite and many other pathogens
to which humans are susceptible. The Handbook of Animal Models of Infection,
(Rouse and Wilson, 1999) observed: ‘Up to this very day, all infectious diseases
affecting humans are far from having appropriate animal models and, even in
those cases where such infections are possible, the symptoms observed in animals
and the course of the disease are often very different from those encountered in
humans’. The recent anthrax attacks in the US mail were initially not taken seriously
enough because experiments on monkeys showed the bacterium not to be fatal until
8–10 000 spores are inhaled. When people died from much smaller doses it became
apparent that this does not apply to humans. Dr. Albert Sabin, inventor of the polio
vaccine, swore under oath before the US Congress that: ‘. . . prevention [of polio]
was long delayed by the erroneous conception of the nature of the human disease
based on misleading experimental models of the disease in monkeys’ (Sabin, 1984).
Space precludes an appraisal of the use of NHPs in multiple sclerosis, cancer,
epilepsy, brain function and behavioural research, amongst many others. For
the purposes of this review, it is sufficient to state that there is a similar pattern
throughout all areas of NHP research: a lack of predictivity for humans, and a
confounding dataset that often contrasts with what is subsequently discovered in
humans.
THE BIOLOGICAL BASIS OF HUMAN/NHP DIFFERENCES
The differences between NHPs and human beings are clear to see, not just in the list
of points made here, but of course more simplistically just by looking at individuals
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from all primate species. Depending on the methods of calculation, humans are 97–
99% genetically identical to chimpanzees, our closest evolutionary relatives. Yet the
physiological and biochemical differences that manifest due to this relatively small
degree of genetic variation are immense (Enard et al., 2002; Hacia, 2001; Gagneux
and Varki, 2001; Watanabe et al., 2004). On a superficial level we don’t look alike
or behave similarly; on a deeper level our biochemical differences mean that we
suffer from different diseases, respond in different ways to infectious agents, have
different metabolisms, and find different substances toxic. In short, an awful lot of
subtle biochemical differences combine to make us very different indeed.
We are now learning why this is so, and it carries through to NHP use in
biomedical research. A growing body of opinion, including many medical and
scientific professionals, now believes that NHPs are just too different from human
beings to serve as ‘surrogate’ humans in this way; they cannot be predictive
of the human situation, and one cannot rely on data from NHP experiments
when extrapolated to humans. NHP research can be manipulated in order to
retrospectively correlate with and ‘confirm’ human data, but this should not be
taken as evidence of its worth. The scientific and medical community at large can no
longer ignore such a substantial body of information: when extrapolated to humans,
NHP research has caused untold amounts of harm, a fraction of which is detailed
here; directly by causing human suffering and death, and indirectly by delaying
medical progress and diverting research funds from more appropriate methodology.
Those small genetic differences between us explain why this is the case. Some
of these differences lie within the structural genes, in which small differences
can completely change a gene’s function and ability to do its job. Most of the
differences, however, are now known to lie within the regulatory regions of our
DNA; particular genes and sections of DNA that are involved in turning other genes
‘on’ and ‘off’ and modifying how their products do their jobs and interact with
one another, in response to a variety of signals and stimuli. These can act highly
promiscuously, and exert ‘avalanche’ effects upon hundreds of other genes. A small
difference, therefore, can have far-reaching and extreme effects. For example,
striking differences have been found in the levels of gene expression between
humans and chimps in the brain and liver (Ruvolo, 2004).
THE WAY FORWARD
Many scientific techniques and methodologies are more relevant to human medicine
and more predictive and reliable for human beings than NHP-oriented research, and
are directly responsible for the great strides we are now making towards treating and
curing the most widespread and debilitating human diseases. Batteries of human-
based tests provide reliable and relevant information on which to base further
research and to speed the translation of research to the bedside.
These technologies include microarrays and other DNA technologies; proteomics
and metabolomics; mathematical and computer modelling; epidemiology; human
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clinical research; myriad in vitro molecular biological techniques; microfluidics
devices harbouring many types of human cells in an almost ‘natural’ environment
and interacting with one another; and many more. Studies of brain function and
neurological disorders account for much NHP research, yet the most dramatic
differences between us and other primates are in the brain. Human brains can
now be studied non-invasively using a huge array of imaging techniques such as
positron emission tomography (PET), magnetoencephalography (MEG), magnetic
resonance imaging (MRI) and functional magnetic resonance imaging (fMRI),
transcranial magnetic stimulation (TMS), EROS (event-related optical signals),
VBM (voxel-based morphometric analysis) and single photon emission computed
tomography (SPECT). These enable the conscious brain to be observed while
engaged in a variety of cognitive tasks (e.g. talking, singing, reading, and writing)
of which NHPs are not even capable. Subtleties such as musical ability and memory
skills can be identified, highlighting the redundancy of knowledge to be gained from
NHPs. The Academy of Life Sciences at Aston University is an example of progress
to be gained from multidisciplinary human clinical research.
Perhaps the most exciting technology with regard to drug development is ‘micro-
dosing’, in which nanogram doses of new drugs are traced through the human body.
Employed as ‘Phase 0’ clinical trials, microdosing provides extensive information
about a drug’s pharmacokinetic properties in a human environment and has already
been endorsed by the FDA (April 2005) and the European Agency for the Evalu-
ation of Medicinal Products (January 2003). The APC recommended that the use
of microdosing in place of NHPs should be encouraged. Several companies exist
whose mission is to develop and/or test drugs in an exclusively human context, such
as Pharmagene, who observe; ‘no animal species is sufficiently similar to man to
act as a wholly reliable surrogate. Indeed there is extensive evidence that the use
of animal (non-human) tissue can result in the generation of potentially misleading
information’ and Biopta, whose rationale is ‘proof of concept in man’.
TIME FOR OBJECTIVITY
The limitations of nonhuman primate research and the risk of excessive faith in its
results have not yet been widely appreciated by many. For a variety of political
reasons, few scientists openly question whether primate models are a reliable
research method. One of the main obstacles to open discussion and debate is that
researchers, threatened by those who oppose their modus operandi, believe that
best strategy is to defend all animal research regardless of its actual value (Gluck
and Kubacki, 1991; Wiebers et al., 1994) and to discourage and actively suppress
criticism from within their ranks (Arluke, 1994; Dunayer, 1993; Kaufman, 1994,
1991).
For the benefit of human medical progress, it is surely time for objectivity,
transparency and honesty in the assessment of NHP models and their contribution
to medical science. Only by ensuring this can we be confident that we are utilizing
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scientific technology to the full, performing the best translational research possible,
and making real progress towards the relief of human suffering and disease.
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